Details for Patent: 12,734,180
Which drugs does patent 12,734,180 protect, and when does it expire?
Patent 12,734,180 protects AKEEGA and is included in one NDA.
This patent has fifty-seven patent family members in eighteen countries.
Drugs Protected by US Patent 12,734,180
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Janssen Biotech | AKEEGA | abiraterone acetate; niraparib tosylate | TABLET;ORAL | 216793-001 | Aug 11, 2023 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF ADULT PATIENTS WITH METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC) RECEIVING GONADOTROPIN-RELEASING HORMONE (GNRH) AGONIST OR BILATERAL ORCHIECTOMY WHEREIN THE CANCER IS ASSOCIATED WITH DELETERIOUS BRCA-MUTATION | ⤷ Start Trial | ||||
| Janssen Biotech | AKEEGA | abiraterone acetate; niraparib tosylate | TABLET;ORAL | 216793-001 | Aug 11, 2023 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF ADULT PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) RECEIVING GONADOTROPIN-RELEASING HORMONE (GNRH) AGONIST OR BILATERAL ORCHIECTOMY WHEREIN THE CANCER IS ASSOCIATED WITH DELETERIOUS BRCA-MUTATION | ⤷ Start Trial | ||||
| Janssen Biotech | AKEEGA | abiraterone acetate; niraparib tosylate | TABLET;ORAL | 216793-002 | Aug 11, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF ADULT PATIENTS WITH METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC) RECEIVING GONADOTROPIN-RELEASING HORMONE (GNRH) AGONIST OR BILATERAL ORCHIECTOMY WHEREIN THE CANCER IS ASSOCIATED WITH DELETERIOUS BRCA-MUTATION | ⤷ Start Trial | ||||
| Janssen Biotech | AKEEGA | abiraterone acetate; niraparib tosylate | TABLET;ORAL | 216793-002 | Aug 11, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF ADULT PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) RECEIVING GONADOTROPIN-RELEASING HORMONE (GNRH) AGONIST OR BILATERAL ORCHIECTOMY WHEREIN THE CANCER IS ASSOCIATED WITH DELETERIOUS BRCA-MUTATION | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,734,180
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2021266409 | ⤷ Start Trial | |||
| Australia | 2021267146 | ⤷ Start Trial | |||
| Australia | 2021269115 | ⤷ Start Trial | |||
| Australia | 2026202227 | ⤷ Start Trial | |||
| Australia | 2026202283 | ⤷ Start Trial | |||
| Brazil | 112022021732 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
